Linked Life Data

20421154

Source:http://linkedlifedata.com/resource/pubmed/id/20421154

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20421154rdf:typepubmed:Citationlld:pubmed
pubmed-article:20421154lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C0460004lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C1517927lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C1135135lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:20421154lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:20421154pubmed:issue3lld:pubmed
pubmed-article:20421154pubmed:dateCreated2010-9-27lld:pubmed
pubmed-article:20421154pubmed:abstractTextErlotinib, an oral tyrosine kinase inhibitor, is active against head-and-neck squamous cell carcinoma (HNSCC) and possibly has a synergistic interaction with chemotherapy and radiotherapy. We investigated the safety and efficacy of erlotinib added to cisplatin and radiotherapy in locally advanced HNSCC.lld:pubmed
pubmed-article:20421154pubmed:languageenglld:pubmed
pubmed-article:20421154pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20421154pubmed:citationSubsetIMlld:pubmed
pubmed-article:20421154pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20421154pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20421154pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20421154pubmed:statusMEDLINElld:pubmed
pubmed-article:20421154pubmed:monthNovlld:pubmed
pubmed-article:20421154pubmed:issn1879-355Xlld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:FerreiraCarlo...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:DiasFernando...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:HerchenhornDa...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:MartinsRenato...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:FontãoKarinaKlld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:FedericoMiria...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:ViegasCélia...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:AraújoCarlos...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:SmallIsabelle...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:BezerraMarcos...lld:pubmed
pubmed-article:20421154pubmed:authorpubmed-author:KnustRenata...lld:pubmed
pubmed-article:20421154pubmed:copyrightInfoCopyright © 2010 Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:20421154pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20421154pubmed:day1lld:pubmed
pubmed-article:20421154pubmed:volume78lld:pubmed
pubmed-article:20421154pubmed:ownerNLMlld:pubmed
pubmed-article:20421154pubmed:authorsCompleteYlld:pubmed
pubmed-article:20421154pubmed:pagination696-702lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:meshHeadingpubmed-meshheading:20421154...lld:pubmed
pubmed-article:20421154pubmed:year2010lld:pubmed
pubmed-article:20421154pubmed:articleTitlePhase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.lld:pubmed
pubmed-article:20421154pubmed:affiliationDepartment of Medical Oncology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil. herchenhorn@hotmail.comlld:pubmed
pubmed-article:20421154pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20421154pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20421154pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:20421154pubmed:publicationTypeClinical Trial, Phase Illd:pubmed